Start here
What is 340B?
340B is a federal drug discount program: eligible hospitals and clinics buy certain outpatient drugs at reduced prices from manufacturers and reinvest savings in care for underserved patients and community services—without using federal appropriations. PBM means pharmacy benefit manager (the middlemen who administer many drug plans). A contract pharmacy is a retail or specialty pharmacy a covered entity partners with so patients can fill prescriptions in their community.
“The pharmacy at my hospital is the only reason I can afford my insulin. Without 340B, I don’t know what I would do.”
— Pennsylvania patient, safety-net hospital (name withheld)
Why it matters: When margins are thin, 340B savings help fund prescriptions, screening, and access in rural and underserved communities.
HAP position
Lawmaker actions
Protect the 340B discount and hospital–pharmacy partnerships.
States and Congress keep debating how 340B works with contract pharmacies—choices that affect whether patients can get discounted meds where they actually get care.
HAP asks lawmakers to protect the program and partnerships hospitals rely on—not add barriers for safety-net patients.
What lawmakers can do
Three concrete actions—each tied to patient and hospital impact.
-
Protect the 340B discount
Impact: Hospitals keep access to the outpatient drug prices Congress set for charity care and community benefit.
-
Defend contract pharmacy partnerships
Impact: Patients can fill prescriptions through local and network pharmacies hospitals contract with—not only one distant site.
-
Oppose rules that shrink access for safety-net patients
Impact: Rural and underserved communities keep an affordable path to medications hospitals are required to support.
Overview
Program scale & terms
A federal discount drug program that helps hospitals serve more patients.
340B is a federal discount that helps eligible hospitals (covered entities) stretch dollars further so more patients get care and affordable medicines—without new taxpayer cost.
Market share
7%
340B share of total U.S. drug market (per HAP Mar 2026 talking points; Commonwealth Fund)
Impact: Benchmarks national scale — see HAP talking points (PDF) and Commonwealth Fund.
Terms used here
- 340B
- Federal program that requires manufacturers to charge certain eligible hospitals and clinics lower prices on outpatient drugs.
- Covered entity
- A hospital or clinic that qualifies for 340B pricing.
- Contract pharmacy
- A community pharmacy that dispenses 340B-discounted drugs on a hospital’s behalf.
- PBM
- Pharmacy benefit manager—coordinates drug benefits for health plans.
The numbers that matter
Four anchors before you open the map and state detail.
Contract pharmacy protection · states
21
With protection
29
Not yet enacted
Impact: The map shows where state law backs contract pharmacy networks.
Community benefit (340B hospitals)
$7.95B
Impact: Dollars hospitals report putting back into community programs and care.
Pennsylvania hospitals in 340B
72
ⓘ
Illustrative context only
$7.95B national community benefit ÷ 72 PA hospitals = ~$110M per hospital. This is a mathematical illustration of national program scale applied to Pennsylvania's footprint — not HAP's estimate of any specific hospital's 340B savings, margin, or community benefit.
Actual amounts vary widely by hospital size, DSH percentage, payer mix, drug category mix, and contract pharmacy network configuration.
Do not use this figure in testimony, press statements, or regulatory filings without facility-specific data.
Hospitals serving patients
Impact: Pennsylvania’s scale in the program for statewide advocacy.
Share of total U.S. drug market (340B)
7%
Uses the 340B discount
Impact: HAP’s March 2026 materials cite Commonwealth Fund for this national scale context.
Trend lines based on published annual figures. Source years and methodologies vary by metric — see methodology section. Data: cited public sources.
What we're fighting for
Protect the 340B discount and hospital–pharmacy partnerships
One clear story: access, fairness, and continuity for patients.
Where things stand
21 states have enacted contract pharmacy protection; 29 remain without enacted protection
Use the map below — blue = protection, gray = no state law yet.
Why trust this
Sources and dates are right here
MultiState, ASHP, America's Essential Hospitals.
Data sources Metric → primary source (expand)
Priority citations: HAP March 2026 PA fact sheet and talking points (PDFs alongside this page). BASIC uses the same state-data.js flags as the full dashboard for the map.
| Metric | Source | As of |
|---|---|---|
| State map & protection counts (50 states; D.C. in data, not in headline totals) | MultiState → ASHP → America's Essential Hospitals; state-data.js |
Mar 2026 |
| $7.95B community benefit (2024); ~9% YoY in narrative | HAP talking points (Mar 2026); 340B Health · AHA reported totals | 2024 / Mar 2026 |
| 179 entity vs 5 manufacturer audits (FY24) | HRSA FY24 audits | FY 2024 |
| 72 PA hospitals; 30% of 235 hospitals; 7% total U.S. drug market (340B) | HRSA OPAIS + HAP; HAP talking points (Mar 2026); Commonwealth Fund | Jan 2026 / Mar 2026 |
| PA 49% / 53% / 49% (rural, loss, L&D) | HAP talking points (Mar 2026); Oliver Wyman for HAP | Mar 2026 / OW report vintage |
| 23% Rx savings (survey avg.) | 340B Health · AHA survey (not audited) | Survey cycle |
| Legal landscape text (BASIC) | HAP Finance & Legal review | Mar 2026 |
Independent government reviews (oversight context)
For agency and advisory perspectives alongside hospital voices (not endorsements):
- U.S. Government Accountability Office — 340B oversight (example product).
- HHS Office of Inspector General
- MACPAC
State map
Who protects contract pharmacy, and who does not
Blue states have enacted protection; gray states have not. Open any state for a short status note.
Click a state on the map. BASIC is local-only; use the full dashboard for filters and deeper analysis.
When state law is silent, hospitals depend on manufacturer rules—not a Pennsylvania statutory shield.
Loading map...
Legal landscape
Abbreviated for IT-safe view. Not legal advice. March 2026.
Judicial
Federal courts have rejected manufacturer challenges to several state contract pharmacy protections; reported outcomes include ties to AR, LA, MO, MN, TN, and RI (e.g., PCMA v. Wehbi, 8th Cir. 2022). Confirm with HAP Legal.
2025 enactments
Colorado, Maine, Ohio, Rhode Island, and Vermont paired protections with reporting or transparency requirements.
Executive; PA
Some governors vetoed proposed protections (Virginia reported). Pennsylvania has no freestanding contract pharmacy shield statute as of March 2026; PA DHS runs the 340B Drug Exclusion List for duplicate Medicaid discounts.
Sources: HAP Mar 2026 PA fact sheet · 340B talking points · MultiState · ASHP · America's Essential Hospitals (state law) · 340B Health · AHA (community benefit) · Commonwealth Fund (7% market context, per HAP) · HRSA Program Integrity FY 2024 (audit counts)
Limitations: State law counts change as legislatures meet. Community benefit totals are self-reported aggregates, not independently audited.
Data transparency & methodology
Figures combine published sources and HAP-curated state law flags. Per-hospital numbers labeled “illustrative” are for context only.
Priority HAP PDFs (March 2026): PA fact sheet · Talking points. Other sources: MultiState · ASHP · America's Essential Hospitals (state law) · 340B Health · AHA (community benefit) · Commonwealth Fund (7% U.S. drug market, per HAP) · HRSA Program Integrity FY 2024 (audit counts)
Verification order (state law): MultiState, then ASHP, then America's Essential Hospitals.
Limitations: State law counts change as legislatures meet. Community benefit totals are self-reported aggregates, not independently audited.
Last updated: March 2026
National program scale, reported community benefit, federal oversight load, and Pennsylvania participation in one scan.
U.S. Drug Market
7%
340B share of total U.S. drug market (HAP Mar 2026; Commonwealth Fund)
Impact: National scale figure from HAP-approved talking points, citing Commonwealth Fund.
Community Benefit
$7.95B
340B community benefits (2024)
Impact: Dollars hospitals report reinvesting in community programs and services.
Oversight
179
Covered entity audits (HRSA FY 2024)
Impact: This reflects the scale of federal review activity for covered entities in the stated period.
Pennsylvania
72
PA hospitals in 340B
Impact: It frames Pennsylvania’s footprint in the program for statewide discussion.
Why this matters to health system leaders
Eligible providers
Who depends on 340B
340B supports safety-net providers in both rural and urban markets, including:
- Children's and cancer hospitals
- Rural critical-access hospitals and safety-net hospitals
- Federally qualified health centers
Oversight credibility
Federal oversight remains real
In FY 2024 federal oversight included meaningful review activity:
Covered entities
179
Audited
Manufacturers
5
Audited
HAP supports parity in oversight between hospitals and manufacturers, not a one-sided accountability standard.
Pennsylvania operating stakes
340B remains materially relevant in PA
72 hospitals — 30% of Pennsylvania’s 235 hospitals — participate, per HAP talking points (March 2026):
49%
Rural
53%
Operating at a loss
49%
Labor & delivery
Community benefit
Reinvesting savings
Patient outcomes come first: lower-cost drugs, screening, and community services. The examples below are typical reinvestment areas; the total shows aggregate reported community benefit.
23 percent average savings on pharma purchases
Free or reduced-price prescriptions
Mobile mammography & cancer screening
Dental care & preventive services
Total community benefits (2024)
$7.95B
9% increase over 2023 — reinvested in community health
Pennsylvania Impact Mode
340B impact estimates for PA
See how policy scenarios affect Pennsylvania hospitals, pharmacies, and patient access. Values are illustrative for advocacy. Current status (below): PA has no state protection today.
72 PA hospitals — program status
Exposed
72 PA hospitals participate; PA has no state protection — rely on manufacturer policies
Pharmacies affected
180
Limited by manufacturer restrictions; narrow networks
Patient access
Constrained
Distance and network barriers to 340B pricing
Community benefit
At risk
Exposed to manufacturer policy changes
PA has no contract pharmacy protection. Programs operate under manufacturer limits. Community benefit and patient access remain vulnerable.
Policy simulator · illustrative scenarios
Strengthen, hold, or roll back protections for the 340B discount
Static snapshot below: "Keep today’s mix" — the current national picture. The full dashboard lets you switch scenarios.
Not a forecast or official estimate. Figures match the dashboard’s built-in scenario table.
Uneven access; ongoing risk.
Hospital–pharmacy partnerships
4.5K
Roughly this many pharmacy partnerships today; many states lack protection.
Patient access to affordable meds
Mixed
Depends on the state—some protected, many not.
Hospital program stability
Uneven
Protected states are on firmer ground.
Patchwork: some hospitals and patients benefit; many stay exposed.
Access to care
Contract pharmacy restrictions hit patient access
Federal rules allow hospitals to use in-house or community pharmacies for 340B. Some drugmakers limit hospitals to one contract pharmacy, which hurts rural and underserved patients when hospitals rely on local pharmacy networks.
Briefing Q&A
Use your browser’s print dialog for a one-page handout. The full dashboard includes a dedicated print control.
Q1: Isn’t 340B just a hospital slush fund?
No. $7.95B in reported community benefit (2024) is documented reinvestment in free prescriptions, cancer screening, dental care, and rural services — up 9% from 2023. HRSA audits 179 covered entities annually to verify compliance.
Q2: Why should manufacturers have to give discounts to large health systems?
340B eligibility is tied to DSH percentage and safety-net status — not system size. Eligible hospitals must serve a disproportionate share of low-income and uninsured patients to qualify. Large systems that qualify do so because of their charity care load.
Q3: Doesn’t 340B create duplicate discounts?
Federal law already prohibits it. HRSA and CMS coordinate exclusion lists so manufacturers cannot be required to provide both a 340B price and a Medicaid rebate on the same drug. Pennsylvania runs its own exclusion list through DHS as an added safeguard.
Q4: Shouldn’t manufacturers be able to limit contract pharmacies?
The statute doesn’t give manufacturers that authority. Courts in 6 states (AR, LA, MO, MN, TN, RI) have upheld state protections against manufacturer restrictions. Unilateral restrictions by manufacturers go beyond what federal law requires and reduce patient access.
Q5: Is 340B too big — 7% of the U.S. drug market?
HAP’s March 2026 talking points frame 7% as the share of the total U.S. drug market flowing through 340B, citing the Commonwealth Fund — a bounded scale context, not “program overreach.” Federal oversight (179 covered-entity audits in FY 2024) continues to verify that covered entities use the program as intended.
Pennsylvania safeguards
PA already prevents duplicate discounts
- Manufacturers are not required to give both a 340B discount and a Medicaid rebate for the same drug.
- State DHS (Department of Human Services) runs the 340B Drug Exclusion List and bills manufacturers for Medicaid rebates, so hospitals may not use 340B-priced drugs on this list.
- Contract pharmacies give non-340B drugs to Medicare Advantage patients, and DHS bills manufacturers for rebates.